Effects of toremifene on neonatal rat uterine growth and differentiation

Biology of Reproduction

Volumn 56, Issue 5, 1997, Pages 1239-1244

  Medlock, Kevin L ^a   Branham, William S ^a   Sheehan, Daniel M ^a,b  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOREMIFENE;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; FEMALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; UTERUS GROWTH;

ANIMALIA; RODENTIA; SESAMUM INDICUM;

EID: 0030896699     PISSN: 00063363     EISSN: None     Source Type: Journal    
DOI: 10.1095/biolreprod56.5.1239     Document Type: Article

References (36)

1. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985; 69:237-238.
2. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86:527-537.
3. Kangas L. Review of the pharmacological properties of toremifene. J Steroid Biochem 1990; 36:191-195.
4. Valavaara R, Pyrhonen S, Heikkinen M, Rissanen P, Blanco G, Tholix E, Nordman E, Taskinen P, Holsti L, Hajba A. Toremifene, a new antiestrogenic compound for treatment of advanced breast cancer. Eur J Cancer Clin Oncol 1988; 24:785-790.
5. Stenbygaard LE, Herrstedt J, Thomsen J, Svendsen KR, Engelholm SA, Dombernowsky P. Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial. Breast Cancer Res Treat 1993; 25:57-63.
6. Haynes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwada WR, Mailhard JA, Jones SE, Vogel CL, Berris RB, Shemano I, Schoenfelder J. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995; 13:2556-2566.
7. Tomas E, Kauppila A, Blanco G, Apaja-Sarkkinen M, Laatikainen T. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol 1995; 59:261-266.
8. Maenpaa J, Sipila P, Kangas L, Karnani P, Gronroos M. Chemosensilizing effect of an antiestrogen, toremifene, on ovarian cancer. Gynecol Oncol 1992; 46:292-297.
9. Ramu A, Glaubiger D, Fuks Z. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res 1984; 44:4392-4395.
10. Wiebe VJ, Benz CC, Shemano I, Cadman TB, DeGregorio MW. Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer. Cancer Chemother Pharmacol 1990; 25:247-251.
11. Fabian C, Sternson L, Barnett M. Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. Cancer Treat Rep 1980; 64:765-773.
12. Styles JA, Davies A, Lim CK, De Matties F, Stanley LA, White IN, Yuan Z-X, Smith LL. Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis 1994; 15:5-9.
13. Hard GC, Iatropoulos MJ, Jordan K, Radi L, Kaltenberg OP, Imondi AR, Williams GM. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res 1993; 53:4534-4541.
14. Branham WS, Sheehan DM, Zehr DR, Medlock KL, Nelson CJ, Ridlon E. Inhibition of rat uterine gland genesis by tamoxifen. Endocrinology 1985; 117:2238-2248.
15. Branham WS, Fishman R, Streck RD, Medlock KL, DeGeorge JJ, Sheehan DM. ICI 182,780 inhibits endogenous estrogen-dependent rat uterine growth and tamoxifen-induced developmental toxicity. Biol Reprod 1996; 54:160-167.
16. Branham WS, Zehr DR, Chen JJ, Sheehan DM. Postnatal uterine development in the rat: estrogen and antiestrogen effects on luminal epithelium. Teratology 1988; 38:29-36.
17. Herbst AL. Summary of the changes in the human female genital tract as a consequence of maternal diethylstilbestrol therapy. J Toxicol Environ Health 1976; 1:13-20.
18. Physicians' Desk Reference, 49th edition. Montvale, NJ: Medical Economics Data Production Company; 1995: 2757-2759.
19. Branham WS, Zehr DR, Sheehan DM. Differential sensitivity of rat uterine growth and epithelium hypertrophy to estrogens and antiestrogens. Proc Soc Exp Biol Med 1993; 203:297-303.
20. Branham WS, Sheehan DM. Ovarian and adrenal contributions to postnatal growth and differentiation of the rat uterus. Biol Reprod 1995; 53:863-872.
21. Sheehan DM, Young M. Diethylstilbestrol and estradiol binding to serum albumin and pregnancy plasma of rat and human. Endocrinology 1979; 104:1442-1446.
22. Branham WS, Zehr DR, Chen JJ, Sheehan DM. Uterine abnormalities in rats exposed neonatally to diethylstilbestrol, ethynylestradiol, or clomiphene citrate. Toxicology 1988; 51:201-212.
23. Fishman RB, Branham WS, Streck RD, Sheehan DM. Ontogeny of estrogen receptor messenger ribonucleic acid+ expression in the postnatal rat uterus. Biol Reprod 1996; 55:1221-1230.
24. Medlock KL, Branham WS, Sheehan DM. Long-term effects of postnatal exposure to diethylstilbestrol on uterine estrogen receptor and growth. J Steroid Biochem Mol Biol 1992; 42:23-28.
25. Kaufman RH, Adam E, Binder GL, Gerthofter E. Upper genital tract changes and pregnancy outcome in offspring exposed in utero to diethylstilbestrol. Am J Obstet 1980; 137:299-308.
26. Ben-Baruch G, Menczer J, Mashiach, Serr DM. Uterine anomalies in diethylstilbestrol-exposed women with fertility disorders. Acta Obstet Gynecol Scand 1981; 60:395-397.
27. Cousins L,. Karp W, Lacey C, Lucas WE. Reproductive outcome of women exposed to diethylstilbestrol in utero. Obstet Gynecol 1980; 56:70-76.
28. Simberg NH, Murai JT, Siiteri PK. In vitro and in vivo binding of toremifene and its metabolites in rat uterus. J Steroid Biochem 1990; 36:197-202.
29. Valavaara R, Kangas L. The significance of estrogen receptors in tamoxifen and toremifene therapy. Ann Clin Res 1988; 20:380-388.
30. Kendall ME, Rose DP. The effects of diethylstilbestrol, tamoxifen, and toremifene on estrogen-inducible hepatic proteins and estrogen receptor proteins in female rats. Toxicol Appl Pharmacol 1992; 114:127-131.
31. Kangas L, Nieminen S-L, Blanco G, Gronroos M, Kallio S, Karjalainen A, Perila M, Sodervall M, Toivola R. A new triphenylethylene compound. Fc-1157a. II. antitumor effects. Cancer Chemother Pharmacol 1986; 17:109-113.
32. White INH, de Matteis F, Davies A, Smith LL, Crofton-Sleigh C, Venitt S, Hewer A, Phillips DH. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 1992; 13:2197-2203.
33. Hemininki K, Widlak P, Hou S-M. DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis 1995; 16:1661-1664.
34. Dragan YP, Vaughan J, Jordan VC, Pitot HC. Comparison of the effects of tamoxifen and toremifene on liver and kidney tumor promotion in female rats. Carcinogenesis 1995; 16:2733-2741.
35. Carmichael PL, Ugwumadu AHN, Neven P, Hewer AJ, Poon GK, Phillips DH. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 1996; 56:1475-1479.
36. Hemminki K, Rajaniemi H, Lindahl B, Moberger B. Tamoxifen-induced DNA adducts in the endometrium of breast cancer patients. Cancer Res 1997; (in press).